The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Quality-of-life outcomes following immunotherapy in multiple myeloma: a study by the EORTC
Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, discusses a study by the European Organisation for Research and Treatment of Cancer (EORTC) investigating quality-of-life outcomes in patients with multiple myeloma treated with CAR T-cells and T-cell engagers. She suggests that as novel efficacious therapies emerge, quality of life may become a primary or co-primary endpoint, and that therapy-specific quality-of-life questionnaires are essential to ensure that patients receive optimal treatment. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that we are approaching times that we are discussing about curing myeloma. At the moment, myeloma has been switched to rather a chronic disease, but the problem is that these patients are on ongoing therapies all the time. The new therapies are achieving quite a really good depth of response and duration of response and I believe that in the near future because we have so efficacious therapies, possibly quality of life will be an ultimate primary or co-primary endpoint...
I think that we are approaching times that we are discussing about curing myeloma. At the moment, myeloma has been switched to rather a chronic disease, but the problem is that these patients are on ongoing therapies all the time. The new therapies are achieving quite a really good depth of response and duration of response and I believe that in the near future because we have so efficacious therapies, possibly quality of life will be an ultimate primary or co-primary endpoint. And that’s why from the EORTC we have, apart from the myeloma 20, we’re currently conducting another study when we address the issue of the therapy-specific quality of life questionnaire covering CAR T-cell, T-cell engager therapies to make sure that when we have brought options of treating our patients with different combination therapies, we need to take into account always the quality of life because we are quite privileged witnessing so many good therapies and if these good therapies can achieve and maintain people’s quality of life that would be the ideal combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
